New combo pill could offer safer cholesterol control for seniors
NCT ID NCT07626840
First seen Jun 07, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This study compares a moderate statin (pitavastatin) combined with ezetimibe against high-intensity statins (atorvastatin or rosuvastatin) in patients aged 75+ with coronary artery disease who need a stent. The goal is to see if the combo is just as good at preventing heart attacks, strokes, and other major events, but with fewer side effects like muscle pain or diabetes risk. 5,000 participants will be followed after their procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pitavastatin and ezetimibe combination (Livalozet 4/10mg)
What this could lead to
If successful, this could offer older heart patients a safer, equally effective cholesterol-lowering option with fewer side effects than high-intensity statins.
What could go wrong
This trial hasn't started yet and is large (5,000 participants), but it's testing non-inferiority, meaning the combo might not be better—just as good. Side effects like muscle pain or liver issues are still possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.